Lynn Marks, MD; Senior infectious diseases physician executive, DDLC Solutions, LLC, Board Member, AN2 Therapeutics (ANTX); Cape May, NJ

Physician board certified in Infectious Diseases with a career long connection to antimicrobial resistance and other major challenges in the infectious disease landscape. Joined what is now GSK in the infectious diseases group, rapidly advanced to global position of leadership over the infectious disease therapeutics organization. Currently serving on MMV’s SAB as Chair of the Development section. Previous member of the NCATS/NIH Advisory Committee and Chair of the Cures Acceleration Network Review Board for NCATS (special government employee). In the AMR space on behalf of GSK, engaged with the DRIVE-AB effort and other stakeholders. Input ranged across clinical trial designs, global Regulatory issues, clinical trial networks, commercialization and reimbursement, and global economic incentive projects and policies. Following retirement from GSK as a Senior Vice President was employed by Tunnell Government Services as a contractor supporting the Biomedical Advanced Research and Development Authority (BARDA). Emphasis on supporting the early evolution of CARB-X, working across multiple organizations in HHS. Reviewed product concepts and proposals as well as tactics and strategies for BARDA and provided views and experiences with a focus on the challenges of AMR and reimbursement.

More recently became a Board member of AN2 Therapeutics, a clinical stage publicly traded biotech company focused on finding new medicines for high unmet medical need infectious diseases, a member of the External Advisory Board for the NIAID/NIH funded Antibacterials Research Leadership Group (ARLG) and formed DDLC Solutions, LLC as an independent consultant with emphasis on infectious disease global clinical development and commercialization strategies.